Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Samankaltaisia teoksia

• Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
  Tekijä: Yoon, Hee-Young, et al.
  Julkaistu: (2020)
• Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
  Tekijä: Yang, Hua, et al.
  Julkaistu: (2016)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  Tekijä: Wu, Shang-Gin, et al.
  Julkaistu: (2020)
• Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
  Tekijä: Chang, Yoon Soo, et al.
  Julkaistu: (2016)
• Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
  Tekijä: Huang-Chih Chang, et al.
  Julkaistu: (2017-03-01)